- For Patients
- Introduction to the Marshall Protocol
-
Length of the MP - Immunopathology
- Managing Immunopathology
- Food and Drink
- Light Restriction
- Suitability of the Marshall Protocol
- Starting the Marshall Protocol
- Working with a Physician
- Phase One Guidelines
- Phase Two/Three Guidelines
- Palliative vs. Curative Treatments
- Patient Interviews on Bacteriality
- Non-MP Treatments
- Glossary
- For Physicians
- Publications and Presentations
- Science Behind Marshall Protocol
- Science Behind Immunopathology
- Science Behind Olmesartan (Benicar)
- Safety of Olmesartan (Benicar)
- Safety of MP Antibiotics
- Phase One Guidelines
- Phase Two/Three Guidelines
- Suitability of the Marshall Protocol
- Physicians' Concerns About the MP
- Notice for Emergency Medical Personnel
- For Researchers
- Publications and Presentations
- Science Behind Marshall Pathogenesis
- Science Behind Vitamin D
- Molecular Activity of Vitamin D and the VDR in Chronic Disease
- Th1 Spectrum Disorder – how chronic inflammatory diseases are related
- Transmission of Bacteria and Onset of Chronic Disease
- Successive Infection and Variability in Disease
- Evolutionary Perspective on Chronic Disease
- Incidence and Prevalence of Chronic Disease
- Evidence that Chronic Disease Is Caused by Pathogens
- About ARF
- Related Sites
Hydroxychloroquine (Plaquenil)
Hydroxychloroquine (Plaquenil) is an anti-malarial medication used for a variety of inflammatory diseases including systemic lupus erythematosus as well as rheumatoid arthritis and Sjogren's Syndrome. Hydroxychloroquine is contraindicated for Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. patients for several reasons.
Hydroxychloroquine is ineffective and dangerous
There are several reasons why use of hydroxychloroquine is advised against.
- If hydroxychloroquine is effective, there is no solid molecular rationale as to why. Some doctors and researchers believe that the drug is immunomodulatory, reducing disease symptoms by limiting inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue.. If so, that action may interfere with immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed., which is necessary for recovery from chronic disease. Further, there is no indication that hydroxychloroquine interferes with the reproduction and survival of the intracellular pathogens which cause chronic disease.
Weaning from hydroxychloroquine
Plaquenil lingers in the system at least 50 days and cannot be taken while on the MP. Dr. Blaney reports he starts his patients on Benicar while they are waiting for Plaquenil to clear their system and has seen no adverse events. He prefers to wait a couple months before starting minocyclineBacteriostatic antibiotic used by Marshall Protocol patients..
Trevor Marshall, PhD
